Identification of novel anti-liver cancer small molecules with better therapeutic index than sorafenib via zebrafish drug screening platform

Han Syuan Lin, Yi Luen Huang, Yi Ruistefanie Wang, Eugene Hsiao, Tsu An Hsu, Hui Yi Shiao, Weir Torn Jiaang, Bonifasius Putera Sampurna, Kuan Hao Lin, Ming Shun Wu, Gi Ming Lai, Chiou Hwa Yuh

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Hepatocellular carcinoma (HCC) ranks as the fourth leading cause of cancer-related deaths worldwide. Sorafenib was the only U.S. Food and Drug Administration (FDA) approved drug for treating advanced HCC until recently, so development of new target therapy is urgently needed. In this study, we established a zebrafish drug screening platform and compared the therapeutic effects of two multiple tyrosine kinase inhibitors, 419S1 and 420S1, with Sorafenib. All three compounds exhibited anti-angiogenesis abilities in immersed fli1:EGFP transgenic embryos and the half inhibition concentration (IC50) was determined. 419S1 exhibited lower hepatoxicity and embryonic toxicity than 420S1 and Sorafenib, and the half lethal concentration (LC50) was determined. The therapeutic index (LC50/IC50) for 419S1 was much higher than for Sorafenib and 420S1. The compounds were either injected retro-orbitally or by oral gavage to adult transgenic zebrafish with HCC. The compounds not only rescued the pathological feature, but also reversed the expression levels of cell-cycle-related genes and protein levels of a proliferation marker. Using a patient-derived-xenograft assay, we found that the effectiveness of 419S1 and 420S1 in preventing liver cancer proliferation is better than that of Sorafenib. With integrated efforts and the advantage of the zebrafish platform, we can find more effective and safe drugs for HCC treatment and screen for personalized medicine.

Original languageEnglish
Article number739
JournalCancers
Volume11
Issue number6
DOIs
Publication statusPublished - Jun 1 2019

Fingerprint

Preclinical Drug Evaluations
Zebrafish
Liver Neoplasms
Hepatocellular Carcinoma
Inhibitory Concentration 50
Therapeutics
cdc Genes
Cell Cycle Proteins
Precision Medicine
Therapeutic Uses
United States Food and Drug Administration
Heterografts
Pharmaceutical Preparations
Protein-Tyrosine Kinases
Embryonic Structures
sorafenib
Neoplasms
Proteins

Keywords

  • Anti-angiogenesis
  • Anti-proliferation
  • Hepatocellular carcinoma (HCC)
  • Patient-derived xenograft
  • Zebrafish drug screening

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Identification of novel anti-liver cancer small molecules with better therapeutic index than sorafenib via zebrafish drug screening platform. / Lin, Han Syuan; Huang, Yi Luen; Wang, Yi Ruistefanie; Hsiao, Eugene; Hsu, Tsu An; Shiao, Hui Yi; Jiaang, Weir Torn; Sampurna, Bonifasius Putera; Lin, Kuan Hao; Wu, Ming Shun; Lai, Gi Ming; Yuh, Chiou Hwa.

In: Cancers, Vol. 11, No. 6, 739, 01.06.2019.

Research output: Contribution to journalArticle

Lin, HS, Huang, YL, Wang, YR, Hsiao, E, Hsu, TA, Shiao, HY, Jiaang, WT, Sampurna, BP, Lin, KH, Wu, MS, Lai, GM & Yuh, CH 2019, 'Identification of novel anti-liver cancer small molecules with better therapeutic index than sorafenib via zebrafish drug screening platform', Cancers, vol. 11, no. 6, 739. https://doi.org/10.3390/cancers11060739
Lin, Han Syuan ; Huang, Yi Luen ; Wang, Yi Ruistefanie ; Hsiao, Eugene ; Hsu, Tsu An ; Shiao, Hui Yi ; Jiaang, Weir Torn ; Sampurna, Bonifasius Putera ; Lin, Kuan Hao ; Wu, Ming Shun ; Lai, Gi Ming ; Yuh, Chiou Hwa. / Identification of novel anti-liver cancer small molecules with better therapeutic index than sorafenib via zebrafish drug screening platform. In: Cancers. 2019 ; Vol. 11, No. 6.
@article{de601a5fb04b467da0b22752454bde56,
title = "Identification of novel anti-liver cancer small molecules with better therapeutic index than sorafenib via zebrafish drug screening platform",
abstract = "Hepatocellular carcinoma (HCC) ranks as the fourth leading cause of cancer-related deaths worldwide. Sorafenib was the only U.S. Food and Drug Administration (FDA) approved drug for treating advanced HCC until recently, so development of new target therapy is urgently needed. In this study, we established a zebrafish drug screening platform and compared the therapeutic effects of two multiple tyrosine kinase inhibitors, 419S1 and 420S1, with Sorafenib. All three compounds exhibited anti-angiogenesis abilities in immersed fli1:EGFP transgenic embryos and the half inhibition concentration (IC50) was determined. 419S1 exhibited lower hepatoxicity and embryonic toxicity than 420S1 and Sorafenib, and the half lethal concentration (LC50) was determined. The therapeutic index (LC50/IC50) for 419S1 was much higher than for Sorafenib and 420S1. The compounds were either injected retro-orbitally or by oral gavage to adult transgenic zebrafish with HCC. The compounds not only rescued the pathological feature, but also reversed the expression levels of cell-cycle-related genes and protein levels of a proliferation marker. Using a patient-derived-xenograft assay, we found that the effectiveness of 419S1 and 420S1 in preventing liver cancer proliferation is better than that of Sorafenib. With integrated efforts and the advantage of the zebrafish platform, we can find more effective and safe drugs for HCC treatment and screen for personalized medicine.",
keywords = "Anti-angiogenesis, Anti-proliferation, Hepatocellular carcinoma (HCC), Patient-derived xenograft, Zebrafish drug screening",
author = "Lin, {Han Syuan} and Huang, {Yi Luen} and Wang, {Yi Ruistefanie} and Eugene Hsiao and Hsu, {Tsu An} and Shiao, {Hui Yi} and Jiaang, {Weir Torn} and Sampurna, {Bonifasius Putera} and Lin, {Kuan Hao} and Wu, {Ming Shun} and Lai, {Gi Ming} and Yuh, {Chiou Hwa}",
year = "2019",
month = "6",
day = "1",
doi = "10.3390/cancers11060739",
language = "English",
volume = "11",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "6",

}

TY - JOUR

T1 - Identification of novel anti-liver cancer small molecules with better therapeutic index than sorafenib via zebrafish drug screening platform

AU - Lin, Han Syuan

AU - Huang, Yi Luen

AU - Wang, Yi Ruistefanie

AU - Hsiao, Eugene

AU - Hsu, Tsu An

AU - Shiao, Hui Yi

AU - Jiaang, Weir Torn

AU - Sampurna, Bonifasius Putera

AU - Lin, Kuan Hao

AU - Wu, Ming Shun

AU - Lai, Gi Ming

AU - Yuh, Chiou Hwa

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Hepatocellular carcinoma (HCC) ranks as the fourth leading cause of cancer-related deaths worldwide. Sorafenib was the only U.S. Food and Drug Administration (FDA) approved drug for treating advanced HCC until recently, so development of new target therapy is urgently needed. In this study, we established a zebrafish drug screening platform and compared the therapeutic effects of two multiple tyrosine kinase inhibitors, 419S1 and 420S1, with Sorafenib. All three compounds exhibited anti-angiogenesis abilities in immersed fli1:EGFP transgenic embryos and the half inhibition concentration (IC50) was determined. 419S1 exhibited lower hepatoxicity and embryonic toxicity than 420S1 and Sorafenib, and the half lethal concentration (LC50) was determined. The therapeutic index (LC50/IC50) for 419S1 was much higher than for Sorafenib and 420S1. The compounds were either injected retro-orbitally or by oral gavage to adult transgenic zebrafish with HCC. The compounds not only rescued the pathological feature, but also reversed the expression levels of cell-cycle-related genes and protein levels of a proliferation marker. Using a patient-derived-xenograft assay, we found that the effectiveness of 419S1 and 420S1 in preventing liver cancer proliferation is better than that of Sorafenib. With integrated efforts and the advantage of the zebrafish platform, we can find more effective and safe drugs for HCC treatment and screen for personalized medicine.

AB - Hepatocellular carcinoma (HCC) ranks as the fourth leading cause of cancer-related deaths worldwide. Sorafenib was the only U.S. Food and Drug Administration (FDA) approved drug for treating advanced HCC until recently, so development of new target therapy is urgently needed. In this study, we established a zebrafish drug screening platform and compared the therapeutic effects of two multiple tyrosine kinase inhibitors, 419S1 and 420S1, with Sorafenib. All three compounds exhibited anti-angiogenesis abilities in immersed fli1:EGFP transgenic embryos and the half inhibition concentration (IC50) was determined. 419S1 exhibited lower hepatoxicity and embryonic toxicity than 420S1 and Sorafenib, and the half lethal concentration (LC50) was determined. The therapeutic index (LC50/IC50) for 419S1 was much higher than for Sorafenib and 420S1. The compounds were either injected retro-orbitally or by oral gavage to adult transgenic zebrafish with HCC. The compounds not only rescued the pathological feature, but also reversed the expression levels of cell-cycle-related genes and protein levels of a proliferation marker. Using a patient-derived-xenograft assay, we found that the effectiveness of 419S1 and 420S1 in preventing liver cancer proliferation is better than that of Sorafenib. With integrated efforts and the advantage of the zebrafish platform, we can find more effective and safe drugs for HCC treatment and screen for personalized medicine.

KW - Anti-angiogenesis

KW - Anti-proliferation

KW - Hepatocellular carcinoma (HCC)

KW - Patient-derived xenograft

KW - Zebrafish drug screening

UR - http://www.scopus.com/inward/record.url?scp=85068701014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068701014&partnerID=8YFLogxK

U2 - 10.3390/cancers11060739

DO - 10.3390/cancers11060739

M3 - Article

AN - SCOPUS:85068701014

VL - 11

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 6

M1 - 739

ER -